Lord's Mark Industries Monitoring Committee Approves ₹200 Crore Rights Issue and ESOP Implementation
Lord's Mark Industries' Fifth Monitoring Committee meeting on January 03, 2026, resulted in unanimous approval of a ₹200 crore rights issue and ESOP plan representing minimum 2% equity capital. The committee reviewed progress on NCLT-ordered capital restructuring, including allotment of 42,65,96,580 shares at 1.25:1 swap ratio, and ratified ₹4,74,170 in monitoring expenses while awaiting BSE trading resumption.

*this image is generated using AI for illustrative purposes only.
Lord's Mark Industries Limited conducted its Fifth Monitoring Committee meeting on January 03, 2026, through video conferencing under the chairmanship of Erstwhile Resolution Professional Mr. Amit C Poddar. The meeting addressed several critical corporate restructuring matters and strategic initiatives as the company works toward resuming trading on the BSE platform.
Capital Restructuring Progress
The Monitoring Committee reviewed significant progress on implementing the NCLT Order dated July 28, 2025. Key developments in the capital restructuring process include the identification of 4,90,051 equity shares held by former promoters for extinguishment and proportionate reduction of public shareholding to a maximum of 5% per shareholder.
The committee noted approval for a major share allotment as part of the amalgamation process:
| Parameter: | Details |
|---|---|
| Share Allotment: | 42,65,96,580 equity shares |
| Face Value: | ₹10.00 per share |
| Swap Ratio: | 1.25:1 |
| Beneficiaries: | Eligible shareholders of Lord's Mark Industries Pvt. Ltd. |
| Proposed Record Date: | November 21, 2025 |
The Erstwhile Resolution Professional has maintained constant communication with BSE and SEBI to finalize implementation and resume trading activities.
Rights Issue Approval
The Monitoring Committee unanimously approved a proposal to raise capital through a rights issue, demonstrating strong support for the company's growth plans:
| Aspect: | Details |
|---|---|
| Capital Target: | Up to ₹200.00 crores |
| Approval Status: | 100% committee support |
| Timing: | Post-resumption of BSE listing and trading |
| Promoter Rights: | Authorized to renounce entitlement to other investors |
The rights issue will proceed once the company's shares resume trading on the BSE platform, following completion of all regulatory compliances and capital structure updates.
Employee Stock Option Plan Implementation
To support expansion into renal care and medical technology sectors, the committee approved creation of an Employee Stock Option Plan (ESOP). The company has recently entered the renal care business through acquisition of RenalX Healthcare Systems Limited, which developed an AI-based dialysis machine.
The ESOP structure includes:
| Component: | Specification |
|---|---|
| Pool Size: | Minimum 2% of equity capital |
| Base Calculation: | 42,65,96,580 existing shares |
| Purpose: | Attract high-caliber professionals |
| Target Sectors: | Renal care and medical technology |
| Geographic Scope: | Domestic and global operations |
The company plans to manufacture and sell AI-based dialysis machines, operate dialysis centers across India, and export products internationally. Additionally, the company has developed a remote patient monitoring system with its own data center, receiving significant demand from the United States and Europe.
Financial and Administrative Matters
The committee ratified monitoring period expenses incurred by the Erstwhile Resolution Professional:
| Period: | November 06, 2025 to January 02, 2026 |
|---|---|
| Total Expenses: | ₹4,74,170.00 |
| Primary Components: | Professional fees and administrative costs |
| Approval Status: | Unanimously ratified |
The expenses primarily comprised the Erstwhile RP's remuneration along with courier charges for various regulatory communications with BSE, SEBI, and the Registrar and Transfer Agent.
The meeting concluded with all agenda items receiving unanimous approval, reflecting strong committee support for the company's strategic direction and regulatory compliance efforts. The company continues working toward full implementation of the NCLT-approved scheme and resumption of trading activities.



























